Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Centessa Pharmaceuticals (CNTA) Change in Cash (2022 - 2025)

Historic Change in Cash for Centessa Pharmaceuticals (CNTA) over the last 4 years, with Q3 2025 value amounting to $6.6 million.

  • Centessa Pharmaceuticals' Change in Cash fell 9754.57% to $6.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$344.2 million, marking a year-over-year decrease of 25399.19%. This contributed to the annual value of $255.2 million for FY2024, which is 19607.59% up from last year.
  • According to the latest figures from Q3 2025, Centessa Pharmaceuticals' Change in Cash is $6.6 million, which was down 9754.57% from -$60.9 million recorded in Q2 2025.
  • Over the past 5 years, Centessa Pharmaceuticals' Change in Cash peaked at $267.7 million during Q3 2024, and registered a low of -$278.1 million during Q1 2025.
  • Over the past 4 years, Centessa Pharmaceuticals' median Change in Cash value was -$43.5 million (recorded in 2023), while the average stood at -$36.3 million.
  • Per our database at Business Quant, Centessa Pharmaceuticals' Change in Cash surged by 91854.78% in 2024 and then crashed by 273392.78% in 2025.
  • Quarter analysis of 4 years shows Centessa Pharmaceuticals' Change in Cash stood at -$51.2 million in 2022, then increased by 15.1% to -$43.5 million in 2023, then surged by 72.84% to -$11.8 million in 2024, then skyrocketed by 155.65% to $6.6 million in 2025.
  • Its Change in Cash stands at $6.6 million for Q3 2025, versus -$60.9 million for Q2 2025 and -$278.1 million for Q1 2025.